

## **INSTITUTIONAL ETHICS COMMITTEE**

PANJAB UNIVERSITY (PUIEC), CHANDIGARH-160014

## **Application Form for Initial Review**

EC Ref. No. (For office use):

General Instructions: a) Tick one or more options as applicable. Mark NA if not applicable

b) Attach additional sheets if required

## **SECTION A - BASIC INFORMATION**

	S									
a) Name of Organization:										
b) Name of Ethics Comm	ittee:									
(c) Name of Principal Inve	stigator:									
(d) Department/Division:		(e) Date of submis	ssion: dd mm yy							
(f) Type of review requested¹:										
Exemption from revie	w   Expedited rev	riew 🗆 Full com	mittee review $\square$							
g) Title of the study:										
A / Gb	(If any):									
Acronym/ Short title,	()									
-	-		number:							
h) Protocol number (If an	y):									
h) Protocol number (If an	y):									
(h) Protocol number (If and	Designation and Qualification	Version r	number:							
(h) Protocol number (If an (i) Details of Investigators Name	Designation and Qualification	Version r	number:							
(h) Protocol number (If an (i) Details of Investigators Name	Designation and Qualification	Version r	number:							
h) Protocol number (If an i) Details of Investigators Name	Designation and Qualification	Version r	number:							
(h) Protocol number (If an (i) Details of Investigators Name	Designation and Qualification	Version r	number:							
(h) Protocol number (If and it) Details of Investigators  Name  Principal Investigator/Gu	Designation and Qualification	Version r	number:							
(h) Protocol number (If and (i) Details of Investigators  Name  Principal Investigator/Gu	Designation and Qualification	Version r	number:							
h) Protocol number (If an i) Details of Investigators Name Principal Investigator/Gu	Designation and Qualification	Version r	number:							
h) Protocol number (If an i) Details of Investigators Name Principal Investigator/Gu	Designation and Qualification uide	Version r	number:							

2.	FUN	NDING DETAILS	AND BUDGET				
	(a)	Total estimated	budget for site:				
		At site		In India	Globally		
	(b)	Self-funding □	] Institutio	nal funding $\Box$ Fundin	a agency (Specify)	. 🗆	
	(6)	Sen randing E	institutio		ig agency (opechy)	<b>_</b>	
		S	ECTION B	- RESEARCH RELA	TED INFOR	MATION	
3.		ERVIEW OF RES					
	(a)	Lay summary	(within 300 wo	rds):			
	(b)	Type of study:					
		Basic Sciences		Clinical		<b>Cross Sectional</b>	
		Retrospective		Epidemiological/		Case Control	
		Prospective		Public Health	_	Cohort	
		Qualitative		Socio-behavioural		Systematic Review	
		Quantitative		Biological samples/ Data			
		Mixed Method	Ц	Any others (Specify)	Ц		
			•••••				•••••
4.	ME	THODOLOGY					
	(a)	Sample size/ n	number of partic	ipants (as applicable)			
		At site		In India	Globally		
		Control group.		Study	group		
		Justification fo	or the sample siz	e chosen (100 words); In case	e of qualitative stu	ıdy, mention the criteria	used for
		saturation					
3Su	mmai	rize in the simplest p	ossible way such tha	t a person with no prior knowledge of	f the subject can easily	understand it.	

	(b)	Is the	re an external lab	oratory	outsourcing in	volved for invest	igations?	Yes □ No □	] na □
	(c)	How	was the scientific	quality	of the study as	sessed?			
		Indep	endent external r	eview	☐ Review by	sponsor/Funder		Review within PI's institution	
			ew within multi-ce rch group	ntre	□ No review				
		Date	of review:					dd mm yy	
		Comr	ments of scientific	comm	ittee, if any (100	) words)			
			SECTIO	ON C:	PARTICIP	ANT RELA	TED I	NFORMATION	
5.	REC	RUITI	MENT AND RESEA	ARCH P	ARTICIPANTS				
	(a)	Туре	of participants in t	the stuc	ly:				
		Healt	thy volunteers $\Box$		Patients 🛘	Vulnerable p	oersons/	Special groups	
		Othe	rs 🗆	(Speci	fy)				
		Who	will do the recrui	tment?					
		Parti	cipant recruitmen	t metho	ods used:				
		Post leafl	ers/  ets/Letters	Socia	adio ads/ al media/ tution website	Patients / For visiting hosp		riends 🗆 Telephone 🗆	
		Othe	ers 🗆	(Spec	ify)				
	(b)	i. W	/ill there be vulne	rable pe	ersons / special	groups involved	?	Yes □ No [	□ AA □
		ii. If	yes, type of vulne	erable p	ersons / specia	l groups			
		С	hildren under 18 y	rs			Pregna	ant or lactating women	
		D	ifferently abled (N	1ental/I	Physical)		Emplo	yees/Students/Nurses/Staff	
		El	derly					tionalized	
			conomically and s				Refuge	ees/Migrants/Homeless	Ш
			erminally ill (stigm		or rare diseases	) 🗆			
		Α	ny other <i>(Specify,</i>	):		<u> </u>			
		iii. Pı	rovide justification	n for ind	clusion/exclusio	n			
		iv. A	re there any addit	ional sa	feguards to pro	tect research pa	rticipant	s?	

(-,	) Is there any reimbursement	there any reimbursement to the participants?								
	If yes, Monetary 🗆	Non-monetary 🗆	Provide	e details						
(d	) Are there any incentives to	<u></u>					Yes 🗆 No	。 □		
	If yes, Monetary 🗆	Non-monetary 🗆	Provide	e details						
(e)	) Are there any participant re	ecruitment fees/ incentive	es for the s	tudy pro	ovided to	the PI / Ins	stitution?			
	If yes, Monetary 🗆	Non-monetary 🗆	Provide	e details			Yes 🗌 No	o 🗆		
. BE	ENEFITS AND RISKS									
(a)	) i. Are there any anticipated If yes, categorize the leve		ogical disc	omforts,	risk to p	articipants	? Yes 🗆 No	o 🗆		
	Less than Minimal risk		Minima	l risk						
	Minor increase over minir	mal risk or low risk	More tl	nan mini	mal risk o	r high risk				
	ii. Describe the risk manage	ement strategy:								
(b	) What are the potential benef	fits from the study?	Yes	No	If yes,	Direct	Indirect			
	For the participant									
	For the society/community									
	For improvement in science									
	Please describe how the bei	nefits justify the risks								
(c)	) Are adverse events expected	in the study <sup>6</sup> ?				Yes	s □ No □ NA			
(c)	Are adverse events expected Are reporting procedures an If Yes, Specify	d management strategies					s□ No□ NA Yes□ No			
	Are reporting procedures an	d management strategies								

(b	)	Version number and da	te of P	articipant Informat	ion Sh	eet (PIS	):						
		Version number and da	te of I	nformed Consent F	orm (I	CF):							
(c	)	Type of consent planne	d for :										
		Signed consent	Verbal/Oral consent		l Witn	nessed consent		Audio-Video (AV) consent					
		Consent from LAR (If so, specify from who		For children<7 yrs parental/LAR consent	s 🗆	min	oal assent from or (7-12 yrs) along parental consent		g :				
(d	l)	Who will obtain the info	rmed	consent?									
		PI/Co-I Nurse/	'Couns	elor 🗆 Resea	rch St	aff $\square$	Other $\square$ (Specif	y) .					
		Any tools to be used											
(е	)	Participant Information	Sheet	(PIS) and Informed	d Cons	ent Forr	m (ICF)						
		English  Loc	al lang	uage 🗆	Ot	her 🗆	(Specify)						
		List the languages in w	hich tr	anslations were do	ne								
		If translation has not been done, please justify											
(f	)	Provide details of consent requirements for previously stored samples if used in the study <sup>7</sup>											
<b>(</b> g	) l	Elements contained in th	ne Part	icipant Information	Sheet	t(PIS) an	nd Informed Conse	nt F	orm (ICF)				
	:	Simple language		Data/ Sample sharir	ng		Compensation for s	npensation for study related injury					
		Risks and discomforts	님	Need to recontact			Statement that con		_				
		Alternatives to participation Right to withdraw		Confidentiality Storage of samples			Commercialization/		_				
		Benefits		Return of research r	aculte		Statement that stud	-	_				
		Purpose and procedure		Payment for particip				e of photographs/ Identifying data  United the control of PI and Member  United the C					
		Others(Specify)		. aye			Secretary of EC						
8. PA	٩Y	MENT/COMPENSATION											
(a	۱ (ا	Who will bear the costs	related	l to participation ar	nd pro	cedures	3 ?						
		РІ 🗆	I	nstitution $\square$		Sponso	r 🛭 Other	ager	ncies 🛘 (specify)				
(b	)	Is there a provision for f	ree tre	eatment of research	relate	ed iniurie			Yes □ No □ N/A	Δ Π			
\"		If yes, then who will pro				-			•				
(c	)	Is there a provision for o	compe	nsation of research	relate	d SAE?	If yes, specify	<b>.</b>	Yes □ No □ N/	Ά 🗆			
		Sponsor   Institut	ional/	Corpus fund $\Box$	Proj	ject grar	nt 🔲 Insurar	nce					
(d	l)	Is there any provision fo	r medi	cal treatment or ma	anager	nent till	the relatedness is	det	ermined for injury to th	1e			
		Is there any provision for medical treatment or management till the relatedness is determined for injury to the participants during the study period? If yes, specify.  Yes  No  N/A											
(0		Is there a provision for a	ncilla	vy care for uprolate	d illno	es during	n the study pariod	 つ If v	vas plaasa spacify				
Э	,	is there a provision for a	aricilidi	y care for unrelated	a mne:	ss during	g the study period	: 11	yes, please specify. Yes □ No □ N/	A□			
		tion on re-consent requirements ge 54 in Section 5.8.	s can be	found at National Ethica	l Guidel	ines for Bio	omedical and Health Re	searc	•				
-	_	undertaking from PI confirming	the san	ne					Version 2.0	05			

9.	STORAGE AND CONFIDENTIALITY												
	(a) Identifying Information: Study Involves samples/data. If Yes, specify	Yes ☐ No ☐ NA ☐											
	Anonymous/Unidentified $\square$ Anonymized: Reversibly coded $\square$ Irreversibly coded	$\square$ Identifiable $\square$											
	If identifiers must be retained, what additional precautions will be taken to ensure that a	access is limited /data is											
	safeguarded? (e.g. data stored in a cabinet, password protected computer etc.)												
	b) Who will be maintaining the data pertaining to the study?												
		Yes 🗌 No 🗎 Maybe 🗎											
	If yes, explain how you might use stored material/data in the future?												
	SECTION D: OTHER ISSUES												
10	A DUDI ICATION DENIETT CHADING AND IDD ICCUES												
10.	D. PUBLICATION, BENEFIT SHARING AND IPR ISSUES	Yes □ No □ NA □											
	(a) Will the results of the study be reported and disseminated? If yes, specify.												
	(b) Will you inform participants about the results of the study?	Yes ☐ No ☐ NA ☐											
	(c) Are there any arrangements for continued provision of the intervention for participants,	if effective, once the											
	study has finished? If yes describe in brief (Max 50 words)	Yes 🗆 No 🗀 NA 🗀											
	(d) Is there any plan for post research benefit sharing with participants? If yes, <i>specify</i>	Yes 🗌 No 🗎 NA 🗎											
	(a) Is there any commercial value or a plan to patent/IDD issues? If yes, planse provide data	ils Vos 🗆 No 🗆 NA 🗆											
	(e) Is there any commercial value or a plan to patent/IPR issues? If yes, please provide deta	iis fes Li No Li NA Li											
	(f) Do you have any additional information to add in support of the application, which is no	t included elsewhere in											
	the form? If yes, provide details.	Yes No D											

## SECTION E: DECLARATION AND CHECKLIST 10

11. DI	ECLARATION (Please tick as applicable)									
	I/We certify that the information provided in this application is complete and correct.									
	I/We confirm that all investigators have approved the submitted version of proposal/rela	ted documents.								
	I/We confirm that this study will be conducted in accordance with the latest ICMR Nation for Biomedical and Health Research Involving Human Participants and other applicable relines.									
	I/We confirm that this study will be conducted in accordance with the Drugs and Cosme Rules 1945 as amended from time to time, GCP guidelines and other applicable regulation									
	I/We will comply with all policies and guidelines of the institute and affiliated/collaborating this study will be conducted.	ng institutions where								
	I/We will ensure that personnel performing this study are qualified, appropriately trained and will adhere to the provisions of the EC approved protocol.									
	I/We declare that the expenditure in case of injury related to the study will be taken care	of.								
	I/We confirm that an undertaking of what will be done with the leftover samples is provide	ded, if applicable.								
	I/We confirm that we shall submit any protocol amendments, adverse events report, si from protocols, progress reports and a final report and also participate in any audit of the									
	I/We confirm that we will maintain accurate and complete records of all aspects of the st	udy.								
	I/We will protect the privacy of participants and assure confidentiality of data and biolog	ical samples.								
	I/We hereby declare that I/any of the investigators, researchers and/or close relative(s), have no conflict of interest (Financial/Non-Financial) with the sponsor(s) and outcome of study.									
	I/We have the following conflict of interest (PI/Co-I):									
_	1									
	2									
	I/We declare/confirm that all necessary government approvals will be obtained as per recer applicable.	quirements wherev-								
Na	ime of PI:									
Sig	gnature:	dd mm yy								
Na	me of Co-PI:									
Sig	Signature: dd mm yy									
Na	me of Guide:									
Sig	gnature:	dd mm yy								
Na	me of HOD:									
Sig	gnature:	dd mm yy								

<sup>10</sup>These formats are adaptable and can be modified by the Ethics Committee members depending on their needs and requirements Acknowledgement for Receipt of Application (Copy to be provided to PI)

12. CHI	ECKLIST											
S. No		Items		Yes	No	NA	Enclosure No	EC Remarks (If applicable)				
ADMI	ADMINISTRATIVE REQUIREMENTS											
1	Cover letter											
2	Brief CV of all Investigato	rs										
3	Good Clinical Practice (G	CP) tr	aining	of investi	gators in	last 3 yea	rs					
4	Approval of scientific con	ee										
5	EC clearance of other cen											
6	Agreement between colla	borat	ting pa	rtners*								
7	MTA between collaboratir	ng pa	rtners*	:								
8	Insurance policy/certificat	te										
9	Evidence of external labo outsourced laboratory stu					n externally	У					
10	Copy of contract or agreem	ent si	gned w	ith the spo	onsor or d	onor agend	у					
11	Provide all significant previous decisions (e.g. those leading to a negative decision or modified protocol) by other ECs/Regulatory authorities for proposed study (whether in same location or elsewhere) and modification(s) to protocol											
PROPO	DSAL RELATED											
12	Copy of the detailed prot	ocol <sup>11</sup>										
13	Investigators Brochure (If	appli	cable f	or drug/b	oiological	s/device tr	rials)					
14	Participant Information SI Form (ICF)(English and tr			nd Partic	ipant Info	ormed Con	sent					
15	Assent form for minors (1)	2-18 y	(ears	English a	nd Transl	ated)						
16	Proforma/Questionnaire/ Guides for Focused Group											
17	Advertisement/material to	o reci	ruit par	ticipants	(fliers, po	osters etc)						
PERMI	SSION FROM GOVERNII	NG A	UTHO	RITIES								
	Other permissions	Req	uired	Not required	Receive	d Applied mm/	-				EC Remarks	
18	CTRI											
19	DCGI											
20	HMSC											
21	NAC-SCRT											
22	ICSCR											
23	RCGM											
24	GEAC											
25	BARC 🗆 🗆											
26	6 Tribal Board 🔲 🖂											
27	Others (Specify)		<u> </u>									
ANY O	THER RELEVANT INFO	RMA	TION/	DOCUM	ENTS RE	LATED T	ОТН	E STU	DY			
	Item		YES	NO	NA	Enclosure	e no.				EC remarks	
28												
29	29											

MTA-Material transfer agreement; CTRI-Clinical Trial Registry-India; DCGI-Drug Controller General of India; HMSC- Health Ministry's Screening Committee; NAC-SCRT- National Apex Committee for Stem Cell Research and Therapy; IC-SCR-Institutional committee for Stem Cell Research; RCGM- Review Committee on Genetic Manipulation; GEAC- Genetic Engineering Approval Committee; BARC- Bhabha Atomic Research Centre

"Refer to National Ethical Guidelines for Biomedical and Health Research Involving Human Participants 2017, section 4 Page no. 35 Box 4.4(b)

Version 2.0 08

<sup>\*</sup>For multicentre research.